Imx instrument

Manufactured by Abbott

Sourced in United States

The IMx instrument is a laboratory analyzer used for immunoassay testing. It is designed to perform automated processing and analysis of samples to detect and quantify specific analytes, such as hormones, drugs, and other biomolecules.

Automatically generated - may contain errors

Lab products found in correlation

Architect instrument, by Abbott (1 mentions) Au400 chemistry analyzer, by Olympus (1 mentions) Crp ul assay, by Fujifilm (1 mentions) Au400 analyzer, by Olympus (1 mentions)

3 protocols using imx instrument

Tacrolimus Concentration Measurement Techniques

Cited 1 time

Check if the same lab product or an alternative is used in the 5 most similar protocols

In the Brisbane dataset, all tacrolimus concentration measurements were made using liquid chromatography-tandem mass spectrometry assay (LC-MS/MS) 24 . In the Oslo dataset, 80% of concentrations were measured with chemiluminescent microparticle immunoassay (CMIA, analyzed on the Architect® instrument, Abbott Laboratories, Abbott Park, IL 25 (link)), 11% with LC-MS/MS 26 (link) and 9% with microparticle enzyme immunoassay (MEIA, analyzed on the IMx® instrument, Abbott Laboratories 27 (link)). In the external evaluation dataset, all concentrations were measured with CMIA. Concentrations (C) measured with CMIA and MEIA were converted to corresponding LC-MS/MS equivalents using an equation derived from linear regression as described previously (Equation 1) 7 (link):

The LC-MS/MS assay used in Brisbane was linear over the range between 0.5 to 50 μg l⁻¹. The imprecision coefficient of variation (CV) was 5%. The LC-MS/MS assay used in Oslo had a lower limit of quantification (LLOQ) of 1.1 μg l⁻¹ and a CV of 5.2%. The CMIA had a LLOQ of 1.0 μg l⁻¹ and CVs of 9% at 2.3 μg l⁻¹ and 6% at 7.0 μg l⁻¹. The MEIA had a LLOQ of 3.0 μg l⁻¹ and CVs of 13% at 5 μg l⁻¹ and 7% at 23 μg l⁻¹.

Størset E., Holford N., Hennig S., Bergmann T.K., Bergan S., Bremer S., Åsberg A., Midtvedt K, & Staatz C.E. (2014). Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling. British Journal of Clinical Pharmacology, 78(3), 509-523.

+ Open protocol

+ Expand

Enzymatic Assays for Metabolic Markers

Check if the same lab product or an alternative is used in the 5 most similar protocols

Fasting serum glucose concentration was determined by the enzymatic hexokinase method (glucose reagent, AU400 chemistry analyzer, Olympus). Fasting serum insulin concentration was determined by a microparticle enzyme immunoassay (IMx insulin reagent) on an IMx instrument (Abbott). Serum CRP concentration was analyzed using an AU400 chemistry analyzer (Olympus) and a highly sensitive turbidimetric immunoassay kit (CRP-UL-assay, Wako Chemicals, Neuss, Germany). The LOD was 0.02 mg/L. Interassay CVs were 3.33% at the mean level of 1.52 mg/L (n = 116) and 2.65% at the mean level of 2.51 mg/L (n = 168). Analyzed samples for fasting glucose, fasting insulin, HOMA-IR, and CRP concentrations were n = 1,951, n = 1,946, n = 1,938, and n = 1,952, respectively, for rs4251961 and n = 1,950, n = 1,945, n = 1,937, and n = 1,951, respectively, for rs6759676.

Herder C., Nuotio M.L., Shah S., Blankenberg S., Brunner E.J., Carstensen M., Gieger C., Grallert H., Jula A., Kähönen M., Kettunen J., Kivimäki M., Koenig W., Kristiansson K., Langenberg C., Lehtimäki T., Luotola K., Marzi C., Müller C., Peters A., Prokisch H., Raitakari O., Rathmann W., Roden M., Salmi M., Schramm K., Swerdlow D., Tabak A.G., Thorand B., Wareham N., Wild P.S., Zeller T., Hingorani A.D., Witte D.R., Kumari M., Perola M, & Salomaa V. (2014). Genetic Determinants of Circulating Interleukin-1 Receptor Antagonist Levels and Their Association With Glycemic Traits. Diabetes, 63(12), 4343-4359.

+ Open protocol

+ Expand

Lipid and Glucose Biomarker Measurements in Fasted Samples

Check if the same lab product or an alternative is used in the 5 most similar protocols

In 2001 and 2007, venous samples were taken after the subject had fasted for 12 hours. Serum total cholesterol levels were measured by the enzymatic cholesterol esterase – cholesterol oxidase method (Cholesterol reagent, Olympus, Ireland). The same reagent was used for estimating HDL-cholesterol levels after precipitation of apoB-containing lipoproteins with dextran sulfate-Mg²⁺. LDL-cholesterol was estimated by the Friedewald formula35 (link) in subjects with triglycerides levels <4.0 mmol/L. The serum triglyceride concentration was assayed using the enzymatic glycerol kinase-glycerol phosphate oxidase method (Triglyceride reagent, Olympus). Serum glucose concentration was determined by the enzymatic hexokinase method (Glucose reagent, Olympus). Apolipoprotein A1 (ApoA1) and B were analysed immunoturbidometrically (Orion Diagnostica, Espoo, Finland). The above mentioned analyses were all performed on an AU400-analyzer (Olympus, Japan). Serum insulin concentration was determined by a microparticle enzyme immunoassay (IMx insulin reagent, Abbott Diagnostics, USA) on an IMx instrument (Abbott). The method has been described in more detail elsewhere36 (link). Fasting plasma high sensitive C-reactive protein (CRP) concentrations were analyzed by means of latex turbidometric immunoassay (Wako Chemicals GmbH, Neuss, Germany).

Fan Y.M., Hernesniemi J., Oksala N., Levula M., Raitoharju E., Collings A., Hutri-Kähönen N., Juonala M., Marniemi J., Lyytikäinen L.P., Seppälä I., Mennander A., Tarkka M., Kangas A.J., Soininen P., Salenius J.P., Klopp N., Illig T., Laitinen T., Ala-Korpela M., Laaksonen R., Viikari J., Kähönen M., Raitakari O.T, & Lehtimäki T. (2014). Upstream Transcription Factor 1 (USF1) allelic variants regulate lipoprotein metabolism in women and USF1 expression in atherosclerotic plaque. Scientific Reports, 4, 4650.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!